TY - JOUR
T1 - Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies
T2 - A single-center study showing lower than expected rates of hospitalization and mortality
AU - Aumann, Shlomzion
AU - Tsubary, Uria
AU - Nachmias, Boaz
AU - Ben Yehuda, Dina
AU - Lavie, David
AU - Goldschmidt, Neta
AU - Vainstein, Vladimir
AU - Libster, Diana
AU - Saban, Revital
AU - Shaulov, Adir
AU - Israel, Sarah
AU - Avni, Batia
AU - Grisariu, Sigal
AU - Bdolah-Amram, Tali
AU - Gatt, Moshe
AU - Zimran, Eran
N1 - Publisher Copyright:
© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
PY - 2023/7
Y1 - 2023/7
N2 - Background: Studies addressing coronavirus disease 2019 (COVID-19) in patients with hematological malignancies have reported mortality rates of up to 40%; however, included predominantly hospitalized patients. Methods: During the first year of the pandemic, we followed adult patients with hematological malignancies treated at a tertiary center in Jerusalem, Israel, who contracted COVID-19, with the aim of studying risk factors for adverse COVID-19-related outcomes. We used remote communication to track patients managed at home-isolation, and patient questioning to assess the source of COVID-19 infection, community versus nosocomial. Results: Our series included 183 patients, median age was 62.5 years, 72% had at least one comorbidity and 39% were receiving active antineoplastic treatment. Hospitalization, critical COVID-19, and mortality rates were 32%, 12.6%, and 9.8%, respectively, remarkably lower than previously reported. Age, multiple comorbidities, and active antineoplastic treatment were significantly associated with hospitalization due to COVID-19. Treatment with monoclonal antibodies was strongly associated with both hospitalization and critical COVID-19. In older (≥60) patients not receiving active antineoplastic treatment, mortality, and severe COVID-19 rates were comparable to those of the general Israeli population. We did not detect patients that contracted COVID-19 within the Hematology Division. Conclusion: These findings are relevant for the future management of patients with hematological malignancies in COVID-19-affected regions.
AB - Background: Studies addressing coronavirus disease 2019 (COVID-19) in patients with hematological malignancies have reported mortality rates of up to 40%; however, included predominantly hospitalized patients. Methods: During the first year of the pandemic, we followed adult patients with hematological malignancies treated at a tertiary center in Jerusalem, Israel, who contracted COVID-19, with the aim of studying risk factors for adverse COVID-19-related outcomes. We used remote communication to track patients managed at home-isolation, and patient questioning to assess the source of COVID-19 infection, community versus nosocomial. Results: Our series included 183 patients, median age was 62.5 years, 72% had at least one comorbidity and 39% were receiving active antineoplastic treatment. Hospitalization, critical COVID-19, and mortality rates were 32%, 12.6%, and 9.8%, respectively, remarkably lower than previously reported. Age, multiple comorbidities, and active antineoplastic treatment were significantly associated with hospitalization due to COVID-19. Treatment with monoclonal antibodies was strongly associated with both hospitalization and critical COVID-19. In older (≥60) patients not receiving active antineoplastic treatment, mortality, and severe COVID-19 rates were comparable to those of the general Israeli population. We did not detect patients that contracted COVID-19 within the Hematology Division. Conclusion: These findings are relevant for the future management of patients with hematological malignancies in COVID-19-affected regions.
KW - COVID-19
KW - anti-CD20 antibodies
KW - hematological malignancies
KW - hematological neoplasms
KW - monoclonal antibodies
UR - http://www.scopus.com/inward/record.url?scp=85153605960&partnerID=8YFLogxK
U2 - 10.1111/ejh.13977
DO - 10.1111/ejh.13977
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37096337
AN - SCOPUS:85153605960
SN - 0902-4441
VL - 111
SP - 135
EP - 145
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 1
ER -